Aoskang Bio (Nantong) Co., Ltd. was established in 2017 and is headquartered in Haimen Biotechnology Park, Nantong City, Jiangsu Province. As a CDMO company focusing on the macromolecule field, ASK Biosciences can provide one-stop CMC solutions from candidate molecules to clinical and commercial production. As a "Party B company with Party A's new drug development concept", the core technical team of Aoscon has rich experience in biologics CMC and registration. Members of the CMC technical team have led the development of INDnabling CMC, Sino-US IND application, NDA On-site inspection (PAI) for production reporting and pre-marketing.

Aoscon Bio has raised a total of 3 billion yuan in financing and invested 2 billion yuan in platform hardware construction, continuing to provide the industry with high-quality CDMO services for biomacromolecule drugs.

The company obtained a drug production license in January 2019, and passed the National Bureau of Administration and the pre-market on-site verification (PAI) for registration of the National Bureau and Provincial Bureau and GMP compliance two-in-one products in March 2021, July 2022 and October 2023. The company undertakes and delivers the CMC development and application work for hundreds of monoclonal antibodies, double antibodies, multi-antibody, ADCs, nano-antibody, fusion protein, FVIII, FVIII-Fc-PEG and other projects.

As a Party B company with the "Party A's new drug development concept", the core technical team of Aoscon Bio has rich experience in biologics CMC and registration. Our CMC technical team members have led the INDnabling CMC development work, Sino-US IND application, NDA production reporting and pre-market on-site verification (PAI) for multiple projects. We provide one-stop research and development and production services for drugs such as monoclonal antibodies, dual antibodies, fusion proteins, and ADCs.